Chris Smith

Chris joins NeoGenomics from OrthoClinical Diagnostics where he served as Chairman and CEO from 2019 to May of 2022. During his leadership, OrthoClinical raised $1.45 billion in funding in a Q1 2021 initial public offering and achieved accelerated revenue growth from 1% annually to low double-digit levels while simultaneously improving profitability. Chris also successfully guided the company through a combination with Quidel that closed in May 2022.

Prior to OrthoClinical, Chris served in key executive leadership positions at Cochlear Limited, a global market leader in implantable hearing solutions with over $1.2 billion in annual revenue. Having initially joined Cochlear as President of Cochlear Americas in 2004, Chris helped grow division revenue from $80 million to over $400 million before being named CEO in 2015. During his tenure as CEO from 2015 to 2018, Chris oversaw a 35% organic improvement in annual revenues and improved profitability.

Location

Castle Rock, United States

Links


Org chart

Sign up to view 14 direct reports

Get started



Offices

This person is not in any offices